Hypersensitivity Pneumonitis Market Size

  • Report ID: 5180
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

Hypersensitivity Pneumonitis Market Size

Hypersensitivity Pneumonitis Market size was valued at USD 1.06 Billion in 2023 and is likely to reach USD 2.32 Billion by 2036, registering around 6.2% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of hypersensitivity pneumonitis is estimated at USD 1.12 Billion. The reason behind the growth is impelled by the increasing prevalence of respiratory diseases across the globe. The third biggest cause of mortality is chronic respiratory conditions caused by risk factors including allergens, occupational dangers, and tobacco use. This has increased awareness regarding such conditions among people, leading to better treatment options for hypersensitivity pneumonitis as well. Each year, asthma accounts for more than 160 000 fatalities worldwide.

The development of non-invasive diagnostic procedures are believed to fuel the hypersensitivity pneumonitis market. Imaging and spirometry are non-invasive techniques used in diagnosis and the measurement of the lung's capacity to inhale and exhale air. For instance, HRCT is a noninvasive, precise diagnostic technology used for the proper diagnosis of chronic hypersensitivity pneumonitis.


Hypersensitivity Pneumonitis Market overview
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5180
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of hypersensitivity pneumonitis is estimated at USD 1.12 Billion.

The hypersensitivity pneumonitis market size was valued at USD 1.06 Billion in 2023 and is likely to reach USD 2.32 Billion by 2036, registering around 6.2% CAGR during the forecast period i.e., between 2024-2036. Increasing prevalence of respiratory diseases across the globe and the development of non-invasive diagnostic procedures are the major factors driving the growth of the market.

North America is predicted to account for the largest share of 37% by 2036, impelled by increasing spending in healthcare.

Pfizer Inc., Svizera Healthcare Pvt. Ltd., Sanofi S.A., Novo Nordisk A/S, Eli lilly and Company, Bayer AG, Sun Pharmaceutical Industries Ltd., Novartis AG, Abbott Laboratories Inc., Astra Zeneca Plc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample